July 25, 2007 09:22 ET

Early Alert Small Cap Trade Opportunity for Wednesday, July 25, 2007: LTUS Increasing Production and Retail Space to Keep Up With Demand!

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Peter Antipatis of Capital Research Group Inc.

WESTON, FL--(Marketwire - July 25, 2007) - announces the following stocks to its Action List: Lotus Pharmaceuticals, Inc. (OTCBB: LTUS), Hoku Scientific, Inc. (NASDAQ: HOKU),, Inc. (NASDAQ: AMZN), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN).

Lotus Pharmaceuticals, Inc. (OTCBB: LTUS) released its catalog of drugs, both currently on the market and those in development for future release. Annual projected sales, from the spotlighted drugs alone, would exceed $50 million. Lotus is opening up stores and production facilities across China to keep up with demand.

Lotus Pharmaceuticals, Inc. owns and operates two Chinese pharmaceutical companies located in Beijing. Together, they form a large comprehensive enterprise, which possesses some of the most advanced pharmaceutical-production equipment used in China. The Company's most recent earnings announcement showed quarterly earnings of $8,289,535, and increase of almost 27% from the previous year, and total revenue for 2006 of over $36 million.

Other stocks highlighted include Hoku Scientific, Inc. (NASDAQ: HOKU): Hot Stocks List, up 1% on 3 million shares,, Inc. (NASDAQ: AMZN): Hot Stocks List, down 3% on 25 million shares, Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN): Hot Stocks List, down 2% on 1 million shares.'s Daily Stock Updates:, a leader in corporate communications and finance, highlights stocks that are in the news, have traded high volume, or experienced a large change in price in recent sessions. The aforementioned commentary is not meant to be indicative of a "long term" view of any of the companies listed. For more go to

All material herein was prepared by CRG Partners, Inc. (CRGP) based upon information believed to be reliable. The information contained herein is not guaranteed by CRGP to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. CRGP is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. CRGP has been compensated by third party shareholders with shares or with cash from the company on behalf of one or more of the companies mentioned in this opinion. CRGP has been compensated one hundred thousand restricted shares of LTUS. For promotional work prior to the licensing of TheSUBWAY to CRGP, CRG was compensated five million four hundred thousand restricted shares of Genesis Technology Group Inc. (GTEC). CRG also received six hundred thousand common shares of GTEC, and additional compensation of ten thousand dollars. CRG also purchased three hundred ten thousand GTEC shares in the open market. CRG has sold GTEC shares, and intends to continue to sell its shares and to purchase and sell additional shares of GTEC. An officer of CRG is the sole owner of a limited liability company (the LLC) that is a member of and owns 25 percent of Genesis Equity Partners (GEP) a limited liability company of which GTEC is a member and owns a fifty one percent interest. GEP is a general partner in a partnership agreement with Lotus Pharmaceuticals, Inc. (OTCBB: LTUS) hereafter "Lotus," a publicly traded company, whereby GEP for a period of 18 months is a non exclusive external consultant in connection with financial and related matters. Under that partnership agreement the members of GEP received Lotus stock; the LLC owned by an officer of CRG received 3,302,400 shares of Lotus stock. The LLC intends to sell its shares of Lotus. GEP also receives a fee of $10,000 per month from Lotus. CRGP intends to sell its shares. CRGP has sold approximately zero LTUS shares to date. CRGP may sell its shares for less than the target price given in this opinion. In addition to any compensation mentioned above, additional compensation can be equal to ten percent of any newly issued or registered securities of the profiled companies. CRGP and its web site are operated under a license from Capital Research Group, Inc., Inc. and One Source Solutions Inc. (Licensors) and CRGP is not the agent of any of the Licensors and CRGP is solely responsible for all statements made herein. CRGP's affiliates, officers, directors and employees intend to buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. CRGP will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

Contact Information